Agenus presents new data at asco highlighting botensilimab's immune activation in mss colorectal cancer

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today presented new translational data at the 2025 american society of clinical oncology (asco) annual meeting. the study demonstrates that botensilimab-based therapy induces a robust and persistent t cell immune response in microsatellite stable (mss), or mismatch repair proficient (pmmr), metastatic colorectal cancer (mcrc)—a tumor type traditionally resistant to immunotherapy and representing approxim.
AGEN Ratings Summary
AGEN Quant Ranking